SpyGlass Pharma Q2 net loss widens on higher expenses

SpyGlass Pharma

06/08/2026 21:21

Overview
US biopharmaceutical firm's Q2 net loss widened yr/yr, driven by higher R&D and admin expenses
Company expects cash and short-term investments to fund operations through 2028
Enrollment in Phase 3 BIM-IOL System trials remains on track, completion expected in 2027

Outlook
Company expects completion of BIM-IOL System Phase 3 enrollment in 2027
Spyglass plans to start BIM-DRS first-in-human trial in H2 2026
Company expects cash to fund operations through 2028

Result Drivers
R&D SPENDING - Higher research and development expenses, mainly from hiring clinical personnel, contributed to increased losses
ADMIN COSTS - General and administrative expenses rose due to higher professional service fees and personnel costs
CLINICAL PROGRESS - Enrollment in Phase 3 BIM-IOL System trials remains on track, with completion expected in 2027

Company press release: ID:nGNXxtbsY

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.59
 
Q2 Loss From Operations
 
-$21.97 mln
 
Q2 Operating Expenses
 
$21.97 mln
 
Q2 Pretax Loss
 
$19.86 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for SpyGlass Pharma, Inc. is $42.00, about 77.4% above its August 5 closing price of $23.68

Reuters Recommended Reads
Aug 6 - Edgewise Therapeutics Q2 net loss widens on higher expenses
Aug 6 - Praxis Precision Q2 net loss widens on higher expenses
Aug 6 - Avalo Therapeutics Q2 net loss widens, driven by higher R&D expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)